InMed Pharmaceuticals Inc. - 8-K Filing

Mentari Therapeutics completes business combination with InMed Pharmaceuticals and reports $32.2M net loss for Q3 2026 (Items: 2.01 Completion of Acquisition or Disposition of Assets, 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $INM

Read the full article at SEC EDGAR

Part of the story InMed Pharmaceuticals Inc. - 8-K Filing (3 articles)

More Regulatory news